Navigation Links
Barr Reports GAAP Earnings of $1.18 Per Share for 2007 and $0.30 Per Share for the Fourth Quarter; Adjusted Earnings Were $3.16 Per Share for 2007 and $0.79 Per Share for the Fourth Quarter
Date:2/28/2008

elopment 667 4,615

Total stock-based compensation expense $4,371 $27,750

As of As of

December 31, December 31,

2007 2006

Cash & cash equivalents $246,492 $231,975

Marketable securities - current and

long-term 304,543 682,692

Accounts receivable 496,636 511,136

Other receivables 86,048 67,462

Inventory 501,207 426,270

Accounts payable & accrued liabilities 442,193 408,763

Working capital 970,854 876,106

Total assets 4,761,627 4,961,862

Total debt 2,079,757 2,677,668

Shareholders' equity 1,866,321 1,465,228

Reconciliation of Adjusted Earnings to GAAP Earnings; EBITDA

To supplement its consolidated financial statements presented in accordance with accounting principles generally accepted in the United States of America ("GAAP"), the Company is providing the supplemental financial information contained below to reflect (1) the adjusted earnings per share effect of certain unusual or infrequent charges or benefits that were taken or received in the year and quarter ended December 31, 2007, and (2) the calculation of EBITDA for each period presented.

Adjusted earnings per share and EBITDA are non-GAAP financial measures. The Company is providing this information, however, because it believes that such information is useful to both management and investors in that it fac
'/>"/>

SOURCE Barr Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. QMed, Inc. Reports July Medicare SNP Enrollments
3. Phlo Affiliate Reports Expanded Coverage to Oregon Border
4. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
5. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
6. Carrington Reports Second Quarter 2007 Results
7. Avitar Reports Third Quarter Financial Results for Fiscal 2007
8. Response Genetics Reports Second Quarter 2007 Financial Results
9. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
10. Transgenomic, Inc. Reports Second Quarter 2007 Results
11. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... ... August 28, 2015 , ... Since the initial launch of FireflySci Inc. (FFS) in ... and excellent customer service. Images such as the Fonz in a lab coat and ... flavor to the humdrum spectroscopy field. , FireflySci is proud to be the ...
(Date:8/27/2015)... ... 2015 , ... Capital Edge Consulting , a nationwide consulting firm that ... their ranking as one of the top 5000 companies listed on the 2015 ... nation. , “It is truly an honor to be recognized as one of America’s ...
(Date:8/27/2015)... 27, 2015 /PRNewswire/ - Portage Biotech Inc. ("Portage") ... Biohaven Pharmaceutical Holding Company Limited (Biohaven), announced today ... study of BHV-0223, a glutamate modulating agent. Biohaven ... and recently obtained clearance from the U.S. Food ... testing. Portage holds 54% equity interest in Biohaven, ...
(Date:8/27/2015)... , Aug. 27, 2015  Asterias Biotherapeutics, Inc. ... emerging field of regenerative medicine, today announced that executives ... in the month of September.  , ... at Rodman & Renshaw,s 17th Annual Global Investment Conference ... at the St. Regis Hotel in New ...
Breaking Biology Technology:Cuvette Manufacturer FireflySci Launches Back to School Deals with Complimentary Shipping On All Orders 2Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 2Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4Asterias Biotherapeutics to Present at Upcoming Investor Conferences 2
... available in German . , They have been ... and now they are making rapid inroads in high performance ... cell phones and digital cameras. The automotive industry, for instance, ... increasingly using them in driver assistance systems from parking ...
... Scarguard Labs, LLC, a closely held company specializing in ... through the use of multi-technology drugs enhanced by a ... received approval from Health Canada to sell Scarguard to ... very pleased to gain approval for retail in our ...
... NEW YORK, Feb. 23, 2011 Stemline Therapeutics, Inc., ... that target cancer stem cells (CSCs), today announced that ... ("Pitt"), for the exclusive worldwide rights to a clinically ... tumor bulk and CSCs. Developed by Dr. Hideho Okada, ...
Cached Biology Technology:UV-transparent coating for image sensors 2Stemline Therapeutics Licenses Phase I/II Brain Cancer Vaccine - Shows Promise in Clinical Trial Conducted at University of Pittsburgh 2Stemline Therapeutics Licenses Phase I/II Brain Cancer Vaccine - Shows Promise in Clinical Trial Conducted at University of Pittsburgh 3
(Date:8/31/2015)... , August 31, 2015 Growing ... technology in government digitization projects to drive India ... recently published TechSci Research report, " India Biometrics Market Forecast ... is projected to grow at a CAGR of ... is anticipated on account of extensive use of biometric technology ...
(Date:8/31/2015)... , Aug. 31, 2015 Research and Markets ... "Saudi Arabia Biomedical Sensors Market - Growth, Trends ... The Saudi Arabia Biomedical Sensors market is ... of 3.64% over the period 2014-2020 The ... to the genetic formulation of each individual. These sensors ...
(Date:8/28/2015)... , August 28, 2015 ... and Training Market by Assessment Type (Pen & Paper ... Brain Training, Corporate Learning, Academic Research), Vertical and Region ... Assessment and Training Market to grow from USD 2.4 ... at a Compound Annual Growth Rate (CAGR) of 25.6% ...
Breaking Biology News(10 mins):India Biometrics Market to Grow at Over 35% Through 2020, Says TechSci Research 2India Biometrics Market to Grow at Over 35% Through 2020, Says TechSci Research 3Saudi Arabia Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts (2014-2020) 2Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 2Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 3Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 4
... difficult to eliminate tumours effectively. Deciphering the strategies ... tumour cells and thus improve the clinical perspectives for ... and CNRS researchers have used two-photon microscopy to demonstrate, ... T lymphocytes infiltrate a solid tumour in order to ...
... discovered that the same ingredient used in dandruff shampoos ... head also can calm overexcited nerve cells inside your ... of the study can be found online in Nature ... result when nerves excessively or inappropriately “fire?in the brain. ...
... have developed two strategies to reactivate the p53 gene in ... The p53 protein is called the "guardian of the genome" ... , Inactivation of p53 can set the stage for the ... for the first time that inactivating the p53 gene is ...
Cached Biology News:How T lymphocytes attack 2How T lymphocytes attack 3Anti-dandruff compound may help fight epilepsy 2Turning a cellular sentinel into a cancer killer 2Turning a cellular sentinel into a cancer killer 3Turning a cellular sentinel into a cancer killer 4
5 minutes from gel band to purified DNA...
Collected from sexually matured, mixed breed, mixed sex guinea pigs....
Sterile concentration of Dithiothreitol (DTT) solution in phosphate buffer (pH 7.0). Dilute contents in one vial (10- fold) to 100 ml. For use in liquefying sputum samples....
Antibody specific for phosphorylattion of histone H3 that occurs during mitosis. Rabbit polyclonal serum. Antigen: Synthetic peptides derived from histone H3, phosphorylated at serines 10 or 28...
Biology Products: